📰 Neil Kumar News
Page 7 - Neil Kumar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Neil Kumar. Real-time updates on events, politics, business and more.
April 8, 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 5th. The shares were sold at an average price of $15.46, for a total value of $1,855,200.00. Following the completion of the transaction, the chief executive officer now directly owns […]
April 8, 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 55,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $15.45, for a total transaction of $857,475.00. Following the completion of the transaction, the chief financial officer now owns […]
April 5, 2023
/PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help...
April 3, 2023
Takeover interest is spurring these two biotech stocks higher.
March 6, 2023
BridgeBio's latest results could set the bar in efficacy for treating the most common cause of short stature.
March 6, 2023
BridgeBio Pharma Inc (NASDAQ:BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 st...
March 6, 2023
- In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03...
March 5, 2023
Renaissance Technologies LLC raised its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 230.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,366,746 shares of the company’s stock after acquiring an additional 953,500 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of BridgeBio […]
February 23, 2023
23.02.2023 - –Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 ...
February 7, 2023
Cowen assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Rating) in a research report report published on Monday morning, The Fly reports. The brokerage issued an outperform rating on the stock. BBIO has been the subject of a number of other research reports. JPMorgan Chase & Co. reduced their price objective on BridgeBio […]